Your browser is no longer supported. Please, upgrade your browser.
Settings
CNCE Concert Pharmaceuticals, Inc. daily Stock Chart
CNCE [NASD]
Concert Pharmaceuticals, Inc.
Index- P/E5.24 EPS (ttm)3.75 Insider Own3.70% Shs Outstand22.81M Perf Week-29.15%
Market Cap447.30M Forward P/E- EPS next Y-2.41 Insider Trans-54.96% Shs Float19.77M Perf Month-28.82%
Income89.20M PEG- EPS next Q-0.43 Inst Own73.60% Short Float3.53% Perf Quarter40.47%
Sales143.90M P/S3.11 EPS this Y-310.10% Inst Trans0.11% Short Ratio1.49 Perf Half Y37.52%
Book/sh8.63 P/B2.27 EPS next Y-161.30% ROA68.90% Target Price26.20 Perf Year121.58%
Cash/sh8.86 P/C2.21 EPS next 5Y- ROE83.60% 52W Range8.61 - 30.71 Perf YTD-24.20%
Dividend- P/FCF4.64 EPS past 5Y-15.60% ROI-59.80% 52W High-36.14% Beta1.68
Dividend %- Quick Ratio28.20 Sales past 5Y-61.10% Gross Margin- 52W Low127.76% ATR1.61
Employees69 Current Ratio28.20 Sales Q/Q-34.60% Oper. Margin62.80% RSI (14)31.00 Volatility11.36% 6.23%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin61.10% Rel Volume1.11 Prev Close19.71
ShortableYes LT Debt/Eq0.00 EarningsFeb 08 BMO Payout0.00% Avg Volume470.05K Price19.61
Recom1.80 SMA20-23.15% SMA50-16.43% SMA20015.56% Volume520,386 Change-0.51%
Jan-12-18Downgrade Mizuho Buy → Neutral $23
Oct-26-17Initiated Mizuho Buy $23
Jul-24-17Initiated H.C. Wainwright Buy $20
Mar-07-17Reiterated Stifel Buy $21 → $31
Jul-01-16Initiated Stifel Buy $23
Sep-22-15Reiterated ROTH Capital Buy $22 → $32
Aug-12-15Initiated Brean Capital Buy $21
Nov-12-14Reiterated ROTH Capital Buy $28 → $21
Mar-10-14Initiated UBS Buy $25
Jan-17-18 06:55AM  Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News Zacks
Jan-16-18 05:50AM  Concert Pharma shares hit low note on patent challenge denial American City Business Journals
Jan-15-18 03:10PM  Concert Pharmaceuticals Plunges on Patent Petition Setback Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Concert Pharmaceuticals and Exact Sciences Corporation ACCESSWIRE
Jan-12-18 03:18PM  Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today Motley Fool -27.20%
01:48PM  Concert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades Benzinga
07:05AM  FDA Grants Fast Track Designation to Concert Pharmaceuticals CTP-543 for the Treatment of Alopecia Areata Business Wire
07:00AM  Concert Pharmaceuticals Announces Patent Trial and Appeal Board Did Not Institute PGR Proceeding Business Wire
Dec-26-17 11:23AM  ETFs with exposure to Concert Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-18-17 07:00AM  Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer Business Wire
Dec-13-17 07:00AM  Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index Business Wire
Dec-11-17 01:42PM  ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017 Capital Cube
Dec-04-17 08:52AM  Concert Pharmaceuticals (CNCE) Soars: Stock Adds 5.7% in Session Zacks
Dec-01-17 10:33AM  ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017 Capital Cube +5.72%
Nov-30-17 09:43AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017 Capital Cube
Nov-13-17 05:42PM  Edited Transcript of CNCE earnings conference call or presentation 9-Nov-17 1:30pm GMT Thomson Reuters StreetEvents +5.93%
Nov-09-17 10:50AM  Concert posts 3Q profit Associated Press
08:23AM  Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update Business Wire
Nov-06-17 08:52AM  Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)? Simply Wall St.
07:00AM  Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial Business Wire
Nov-02-17 07:00AM  Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences Business Wire
Oct-19-17 04:30PM  Why General Electric, Concert Pharmaceuticals, and NVR Jumped Today Motley Fool +18.19%
01:00PM  Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent Business Wire
Oct-17-17 10:10AM  Concert Pharmaceuticals, Inc. Value Analysis (NASDAQ:CNCE) : October 17, 2017 Capital Cube
Oct-16-17 08:33AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : October 16, 2017 Capital Cube
Sep-21-17 10:18AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : September 21, 2017 Capital Cube
Aug-31-17 07:00AM  Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference Business Wire
Aug-24-17 10:18AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 05:26PM  Concert Pharmaceuticals, Inc. Value Analysis (NASDAQ:CNCE) : August 23, 2017 Capital Cube
Aug-22-17 10:20AM  Zacks.com featured highlights: AppFolio, Columbus McKinnon, Concert Pharmaceuticals, Aceto and Liberty Media Zacks
09:01AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 22, 2017 Capital Cube
Aug-13-17 05:24PM  Edited Transcript of CNCE earnings conference call or presentation 8-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 10:08AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : August 11, 2017 Capital Cube
Aug-08-17 11:55PM  Concert reports 2Q loss Associated Press
07:00AM  Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update Business Wire
05:40AM  Investor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 07:00AM  Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017 Business Wire
Jul-25-17 04:01PM  Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656 Business Wire
Jul-24-17 07:00AM  Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex Business Wire +14.75%
Jul-18-17 08:48AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : July 18, 2017 Capital Cube
Jul-10-17 08:20AM  FDA lifts hold on Concert Pharma's study testing hair loss drug Reuters
07:40AM  FDA lifts hold on Concert Pharma's hair loss drug Reuters
07:30AM  FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543 Business Wire
Jul-07-17 09:37AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : July 7, 2017 Capital Cube
Jun-26-17 05:45PM  Concert Pharmaceuticals, Inc. Value Analysis (NASDAQ:CNCE) : June 26, 2017 Capital Cube
Jun-23-17 08:13AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : June 23, 2017 Capital Cube
Jun-12-17 07:00AM  Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital Business Wire
May-30-17 07:00AM  Concert Pharmaceuticals to Present at Upcoming Investor Conferences Business Wire -8.88%
07:00AM  Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws Business Wire
May-24-17 10:00AM  Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals Business Wire
May-22-17 06:29PM  Vertex Undergoes FTC Scrubbing for Deal on CF Treatment TheStreet.com
07:00AM  Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act Business Wire
May-18-17 10:21AM  Concert Pharma Falls After Clinical Hold on Hair Loss Drug Zacks
May-17-17 12:39PM  FDA places clinical hold on Concert Pharma's hair loss drug Reuters -7.48%
09:52AM  Hold on Concert's Hair Loss Trials Pushes Shares Down 10% TheStreet.com
09:33AM  Concert Pharma stock drops 10% after FDA puts hair loss drug on clinical hold MarketWatch
07:30AM  Concert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial Business Wire
May-04-17 03:49PM  ETFs with exposure to Concert Pharmaceuticals, Inc. : May 4, 2017 Capital Cube
08:50AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : May 4, 2017 Capital Cube
May-03-17 11:14AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017 Capital Cube
May-02-17 12:55PM  Edited Transcript of CNCE earnings conference call or presentation 2-May-17 12:30pm GMT Thomson Reuters StreetEvents
07:23AM  Concert reports 1Q loss Associated Press
07:15AM  Investor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call Accesswire
07:00AM  Concert Pharmaceuticals Reports First Quarter 2017 Financial Results Business Wire
06:30AM  Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata Business Wire
Apr-25-17 07:00AM  Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences Business Wire
Apr-07-17 04:12PM  ETFs with exposure to Concert Pharmaceuticals, Inc. : April 7, 2017 Capital Cube
Mar-26-17 02:00PM  Why Concert Pharmaceuticals Is Music to Investors' Ears TheStreet.com
02:00PM  Why Concert Pharmaceuticals Is Music to Investors' Ears
Mar-24-17 10:50AM  Concert rebuffed $250M buyout offer from Vertex before CF drug deal at bizjournals.com
10:50AM  Concert rebuffed $250M buyout offer from Vertex before CF drug deal American City Business Journals
05:32AM  Will Concert Pharmaceuticals (CNCE) Continue to Surge Higher? Zacks
Mar-17-17 10:15AM  Moving Average Crossover Alert: Concert Pharmaceuticals (CNCE) Zacks
Mar-15-17 09:22AM  After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead Zacks
Mar-11-17 12:35AM  [$$] Charting the Market at Barrons.com
Mar-10-17 12:07PM  3 Biotech Stocks to Buy in March Motley Fool
12:07PM  3 Biotech Stocks to Buy in March at Motley Fool
Mar-09-17 01:04PM  CONCERT PHARMACEUTICALS, INC. Financials
11:18AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017 Capital Cube
11:18AM  Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
Mar-08-17 09:30AM  RDInvesting.com: Coverage Initiated on Concert Pharmaceuticals, Price Surges Accesswire +5.11%
Mar-07-17 05:04PM  Concert Pharmaceuticals, Inc.: Strong price momentum but will it sustain? Capital Cube
05:04PM  Concert Pharmaceuticals, Inc.: Strong price momentum but will it sustain?
01:55PM  Harry Boxers six biotechnology stocks to watch at MarketWatch
10:53AM  Vertex to Buy Concert's Cystic Fibrosis Candidate for $160M
07:16AM  Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : CNCE-US : March 7, 2017
Mar-06-17 01:45PM  Mondays Top Health Care Stocks Screaming Higher +62.07%
01:27PM  Edited Transcript of CNCE earnings conference call or presentation 6-Mar-17 1:30pm GMT
12:45PM  $160M deal with Concert helps Vertex maintain dominance in cystic fibrosis at bizjournals.com
11:53AM  Why Concert Pharmaceuticals Stock Is Soaring Today at Motley Fool
07:57AM  What You Must Know About Cystic Fibrosis Drug CTP-656 at TheStreet
07:56AM  Concert Pharma shares rally 34% on news Vertex to pay up to $250 million for cystic fibrosis drug at MarketWatch
07:34AM  Concert reports 4Q loss
07:23AM  CONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations a
07:15AM  Concert Pharmaceuticals Reports Year Ended 2016 Financial Results Business Wire
07:01AM  Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma
Mar-04-17 10:00AM  Concert Pharmaceuticals Presents CTP-543 Phase 1 Results at American Academy of Dermatology Annual Meeting Business Wire
Mar-02-17 07:00AM  Concert Pharmaceuticals to Report Full Year 2016 Results on March 6, 2017, and Present at Upcoming Investor Conferences Business Wire
Jan-23-17 05:32PM  Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALDRICH RICHARDDirectorJan 19Sale19.6610,000196,55041,946Jan 19 04:34 PM
ALDRICH RICHARDDirectorJan 18Sale19.4010,000193,95046,946Jan 19 04:34 PM
ALDRICH RICHARDDirectorJan 17Sale18.9910,000189,90051,946Jan 19 04:34 PM
ALDRICH RICHARDDirectorJan 16Option Exercise3.6521,23677,405308,211Jan 18 04:26 PM
ALDRICH RICHARDDirectorJan 16Sale19.2710,000192,65056,946Jan 18 04:26 PM
ALDRICH RICHARDDirectorJan 16Sale19.0821,236405,183286,975Jan 18 04:26 PM
BVF PARTNERS L P/IL10% OwnerDec 19Sale26.651,282,85634,188,112122,496Dec 21 07:40 PM
Barrett Ronald WDirectorDec 04Option Exercise3.6514,15651,59914,156Dec 06 04:48 PM
Barrett Ronald WDirectorDec 04Sale24.7014,156349,6530Dec 06 04:48 PM
Tung Roger DChief Executive OfficerNov 17Option Exercise4.587,34033,617626,305Nov 20 04:12 PM
Stuart NancyChief Operating OfficerNov 14Option Exercise4.584,21519,305105,117Nov 15 04:09 PM
BVF PARTNERS L P/IL10% OwnerOct 19Buy15.84331,9165,256,7201,619,249Oct 23 05:43 PM
Lynch RyanPFO, PAOSep 14Option Exercise9.463,50033,1109,500Sep 18 04:40 PM
Lynch RyanPFO, PAOSep 14Sale14.513,50050,7856,000Sep 18 04:40 PM
Silverman RobertSenior VP, General CounselMar 09Option Exercise1.1330,96634,99251,075Mar 13 04:14 PM
Stuart NancyChief Operating OfficerMar 08Option Exercise1.132,0982,37141,049Mar 09 06:44 PM